GLSI Latest Headlines

GLSI More Than Doubles Cash Balance, Projecting Funding Beyond 2026 Amid Encouraging FLAMINGO-01 Data

Market Chameleon (Tue, 27-Jan 8:26 AM)

FDA Approves Commercial GP2 Use in FLAMINGO-01: Phase III Data Indicates Up to 80% Reduction in Breast Cancer Recurrence

Market Chameleon (Thu, 22-Jan 10:33 AM)

FDA Greenlights Commercially Manufactured GP2 for FLAMINGO-01: Early Data Shows 80% Reduction in Recurrence Rate

Market Chameleon (Thu, 22-Jan 7:07 AM)

GLSI Extends Officer and Director Lock-Up Through 2026 as Phase III Data Shows Up to 80% Reduction in Breast Cancer Recurrences

Market Chameleon (Tue, 30-Dec 11:06 AM)

GLSI Extends 6-Year Director and Officer Lock-Up—Early Phase III Data Suggests 80% Reduction in Breast Cancer Recurrences

Market Chameleon (Mon, 29-Dec 11:09 AM)

GLSI Extends 6-Year Lock-Up: Aligns Insiders With Long-Term Investors as Phase III Data Impresses

Market Chameleon (Mon, 29-Dec 8:41 AM)

GLSI’s FLAMINGO-01 Study Shows Promising 80% Drop in Breast Cancer Recurrence—How Corporate Strategy Bolsters the Outlook

Market Chameleon (Mon, 22-Dec 10:37 AM)

GLSI Highlights 80% Reduction in Breast Cancer Recurrence—FLAMINGO-01 Data Points to Potential Step Forward in Immunotherapy

Market Chameleon (Mon, 22-Dec 9:37 AM)

Greenwich LifeSciences Reports Preliminary 80% Reduction in Breast Cancer Recurrence for FLAMINGO-01 Non-HLA-A*02 Arm

Market Chameleon (Mon, 15-Dec 10:29 AM)

Greenwich LifeSciences Reports 80% Reduction in Breast Cancer Recurrence: Early Data from FLAMINGO-01 Impresses

Market Chameleon (Mon, 15-Dec 7:05 AM)